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Background: Chronic obstructive pulmonary disease (COPD) remains a significant public health burden. Non-invasive
ventilation (NIV) is a method of supported breathing used as standard care for acutely unwell patients in hospital
with COPD, but there is uncertainty around the potential benefits of using NIV in the treatment of stable patients in
a non-hospital setting. This is a protocol for systematic reviews of the clinical and cost-effectiveness of NIV in this
context, being undertaken in support of a model based economic evaluation.
Methods/Design: Standard systematic review methods aimed at minimising bias will be employed for study
identification, selection and data extraction for both the clinical and economic systematic reviews. Bibliographic
databases (for example MEDLINE, EMBASE) and ongoing trials registers will be searched from 1980 onwards. The
search strategy will combine terms for the population with those for the intervention. Studies will be selected for
review if the population includes adult patients with COPD and hypercapnic respiratory failure, however defined.
Systematic reviews, randomised controlled trials and observational studies (with n >1) will be included, and quality
assessment will be tailored to the different study designs. The primary outcome measures of interest are survival,
quality of life, and healthcare utilisations (hospitalisation and Accident and Emergency attendances). Meta-analyses
will be undertaken where clinical and methodological homogeneity exists, supported by predefined subgroup
analyses where appropriate. A systematic review of the evidence on the cost-effectiveness of non-hospital NIV will
be completed, and a model-based cost-utility analysis undertaken to determine the cost-effectiveness of
non-hospital-based NIV compared with standard care.
Discussion: These reviews will attempt to clarify the clinical effectiveness of non-hospital NIV in COPD patients as well
as the cost-effectiveness. The findings may indicate whether NIV in a non-hospital setting should be considered more
routinely in this patient group, and what the likely cost implications will be.
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Chronic obstructive pulmonary disease (COPD) is a pro-
gressive lung disease, characterised by non-reversible air-
flow obstruction, mostly affecting middle-aged or elderly
people who have smoked [1]. It is projected that COPD
will be the third leading cause of death worldwide by
2020 [2]. Currently, treatment is mainly symptomatic
and aims to slow down disease progression. The main
evidence-based treatments are inhaled agents, such as
bronchodilators [1], and pulmonary rehabilitation [3].
Patients will have periods of no change in symptoms,
and this is often considered a stable state.
As the disease progresses the lungs are unable to per-
form two of their basic functions: to get oxygen to the
bloodstream, and to eliminate carbon dioxide. Hypoxia
is the presence of low oxygen levels and long-term oxy-
gen therapy (LTOT) is considered in selected patients
[1]. Hypercapnia describes a high carbon dioxide level,
the presence of which in a stable patient is a poor prog-
nostic sign [4]. When the respiratory system fails like
this, a patient could be considered to be in the end stage
of their disease. Classically, end-stage COPD would be
defined as those patients in the terminal stage of their
disease, likely to die within months – a situation that is
not always clear [5]. Alternatively, it might be defined as
those who have developed chronic respiratory failure
and remain symptomatic on maximal therapy, with no
hope of cure.
Non-invasive ventilation (NIV) is a method of provid-
ing ventilatory support via a mask, without the place-
ment of an endotracheal tube [6]. It is commonly used
in the hospital setting as standard care for acutely unwell
patients with COPD [7]. As the technology has im-
proved and NIV devices have become less cumbersome,
an increasing number of patients have been able to use
the devices outside of hospital [8]. This includes patients
with chronic respiratory failure due to kyphoscoliosis
and neuromuscular disorders, for whom domiciliary
NIV is an established treatment. Some centres also ad-
vocate NIV in a domiciliary setting for stable COPD
patients with chronic hypercapnic respiratory failure.
Physiological studies have shown improvements in lung
function and carbon dioxide levels thought to be due to
eliminating nocturnal hypoventilation [9]. Some evi-
dence suggests that it prevents episodes of recurrent
acute hypercapnic respiratory failure and hospital admis-
sions [10].
However based on a recent systematic review of ran-
domised controlled trials (RCTs), evidence on the benefit
of home NIV in this patient group remains inconclusive,
particularly regarding long-term outcomes [11]. Varia-
tions between the included RCTs in terms of study
methods and physiological or clinical outcomes mea-
sured, together with a lack of adjustment for clinicalvariables (such as oxygen use or prior acute NIV use)
have limited the conclusions that can be drawn. Further-
more the RCTs, for the most part, appear to have insuf-
ficiently long follow-up periods to capture outcomes
relating to survival, long-term quality of life (QoL), exac-
erbations over the long term, adverse events or adher-
ence rates, all of which are important in considering
cost-effectiveness. Scoping searches suggest that obser-
vational studies may have included larger sample sizes,
longer follow-up periods, additional outcome measures
and less restrictive inclusion criteria than randomised
trials and thus may have wider applicability.
Cost or cost-effectiveness evidence of non-hospital
NIV in patients with stable end-stage COPD is sparse.
There are no systematic reviews of the cost-effectiveness
of non-hospital NIV. Some economic evaluations have
been undertaken either in parallel with clinical trials or
through audits of patient records [10,12]. However, they
appear not to be based on systematic review of clinical
effectiveness, therefore, a robust evaluation of the litera-
ture and development of a new economic model is
warranted.
Study design
Aims and objectives
The aim is to undertake a systematic review of the evi-
dence on the clinical and cost-effectiveness of home or
wider non-hospital-based NIV in patients with stable,
end-stage COPD (however defined).
Clinical effectiveness
 A review of the existing systematic reviews of RCTs
on the clinical effectiveness of non-hospital-based
NIV.
 A systematic review of RCTs on the clinical
effectiveness of non-hospital-based NIV.
 A systematic review of observational studies on the
clinical effectiveness of non-hospital-based NIV.
Cost-effectiveness
 A systematic review of the evidence on the
cost-effectiveness of non-hospital-based NIV.
 A model-based cost-utility analysis to determine the
cost-effectiveness of non-hospital-based NIV.
Methods
Standard systematic review methodology aimed at mini-
mising bias will be employed. The National Institute of
Health Research (NIHR), Health Technology Assessment
(HTA) programme, has ethically approved this review.
This protocol is registered with PROSPERO (2012:
CRD42012003286).
Dave et al. Systematic Reviews 2014, 3:32 Page 3 of 8
http://www.systematicreviewsjournal.com/content/3/1/32Searches
The following sources will be searched for both clinical
and cost-effectiveness reviews:
 Bibliographic databases - MEDLINE, MEDLINE
In Process and EMBASE via Ovid, CINAHL via
EBSCO, Cochrane Library (CDSR, DARE, HTA,
NHS EED and CENTRAL databases), Science
Citation Index (ISI)
 Current controlled trials metaRegister, ISRCTN
database, UKCRN, WHO ICTRP Portal and
ClinicalTrials.gov for ongoing studies
 Specialist abstract and conference proceeding
resources (British Library’s ZETOC and ISI
Proceedings)
 Consultation with experts in the project research
team field
 Checking of citation lists of included studies and
relevant systematic reviews
 Contact with study authors and researchers of
ongoing trials
Given that the main co-intervention/comparator, LTOT,
has been in routine use since the 1980s, searches will be
run from this time point. The strategies will include a
combination of text words and index terms relating to
NIV and COPD as appropriate. There will be no language
restrictions applied to the searches. Study design filters
will not be used. Search results will be entered into elec-
tronic databases (Reference Manager v11 Thomson ISI
ResearchSoft) to facilitate record keeping, duplicate re-
moval, study selection and document writing.
Titles (and abstracts where available) of articles identi-
fied by the searches will be screened by two reviewers,
independently, for relevance to the review question
using pre-specified screening criteria. This process will
be aimed at removing non-relevant studies. Hard copies
of relevant articles will be acquired and assessed against
the inclusion criteria (see below) specific to the review
being undertaken by two reviewers independently. Dis-
crepancies between reviewers will be resolved by discus-
sion or by referring to a third reviewer. Where necessary,
translation (full/part) of non-English language articles will
be undertaken to facilitate this process and subsequent
reviewing; the review team has access to a wide range of
translators. The study selection process will be illustrated
using a PRISMA flow diagram [13]. Reference manage-
ment software will be used to record reviewer decisions,
including reasons for exclusion.
Clinical effectiveness
Selection criteria
A sample search strategy, for the clinical effectiveness
review, for MEDLINE is provided in Appendix 1.Study design
Systematic reviews will be included in order to obtain an
overview of the existing evidence base. RCTs will be
included with no restrictions on the type of RCT (for ex-
ample parallel, cross-over). In view of the steady deteri-
oration in the health of patients with severe COPD,
however, it seems unlikely that cross-over studies will be
a suitable method to make unbiased comparisons of the
long-term efficacy of home NIV. All observational
evidence will be obtained, whether controlled or uncon-
trolled, in order to gain an overview of existing observa-
tional evidence. Uncontrolled observational studies will
be used where primary outcomes are not reported in the
control studies, or, where uncontrolled studies have lon-
ger follow-up for these outcomes.
Patient group
The patient group will be adult patients with stable end-
stage COPD plus chronic hypercapnic respiratory failure,
who have required assisted ventilation (whether invasive
or non-invasive) during an exacerbation or who are hy-
percapnic or acidotic on LTOT, providing they do not
require treatment in hospital. The criteria for specifying
the population are broad, to include any adult patients
with COPD and hypercapnic respiratory failure, however
defined, and inclusion will not be restricted by disease
severity. Where a study contains a mixed population, the
study will be included, but inclusion into analysis will only
be possible where data are available separately for the rele-
vant population or if the majority of the population are
relevant. In the latter case, such a study’s effect on sum-
mary data will be investigated by sensitivity analyses.
Technology
Studies of any form of NIV will be included, whether
continuous or intermediate, added to (any form of)
standard care. Previous research has shown that patients
in acute settings show improvement after four hours
[14], however, study inclusion will not be restricted by
length of daily use.
Comparators/control
For controlled studies
a) Any form of standard care with no NIV; it is noted
that both the setting and the nature of standard care
in the absence of treatment with NIV may be
different to that of treatment with NIV; such
differences will not affect inclusion/exclusion
decisions, but will be noted and commented upon
and considered in the analyses.
b) Studies comparing alternative methods of NIV will
also be included. The main difference is likely to be
whether NIV is set at pressure or volume controlled.
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hours of use per day.
Setting
Home or wider non-hospital setting, operationally this
equates to a non-hospital environment.
Outcome
Studies will be included if they contain any outcomes re-
lated to patient wellbeing, healthcare service utilisation
and/or patient carers. Based primarily on the need to in-
form an economic model, we consider the main out-
comes for the review to be:
Primary outcomes
 survival
 QoL with validated questionnaires for patient
and carer (for example EQ5D, SF-36, St George’s
Respiratory Questionnaire)
 exacerbations (and requirements for associated
medication)
 hospitalisations
 Accident and Emergency admissions
Secondary outcomes
 other healthcare resource use (for example primary
care, training)
 lung function (for example, forced expiratory
volume in one second (FEV1), forced vital capacity
(FVC))
 blood gases (for example, partial pressure of carbon
dioxide in arterial blood (PaCO2))
 dyspnoea
 (serious) adverse events (for example, barotrauma,
pneumonia, nasal skin lesions)
 other patient- or carer-related outcomes such as
quality of sleep, activities of daily living and
acceptability
 adherence/compliance rates
Data extraction
Data extraction will be conducted independently by two
reviewers using a standardised extraction form. Dis-
agreements will be resolved through discussion or refer-
ral to a third reviewer. For each study, the data required
on (but not limited to) the following will be sought:
Study characteristics
 country of origin
 study design
 setting
 sample size
 length of follow-upPopulation
 patient inclusion and exclusion criteria
 patient characteristics
 proportion on LTOT
Intervention/comparator
 NIV versus standard care or NIV versus alternative
NIV
 details of standard care (including additional oxygen
therapy)
 type of NIV equipment; pressure or volume
controlled
 length of nocturnal/daytime NIV
 patient training/education provided
 run-in period (duration/setting)
 patient adherence/compliance (how assessed/
reported)Results
 completeness of follow-up
 outcome measures
 statistical methods employed
 findings
 effect sizes and associated uncertaintyQuality assessment
Data will be extracted to allow quality assessment of the
included studies. Study quality will be assessed using
tools specific to a given study design. For systematic re-
views, the AMSTAR checklist will be used [15]. The risk
of bias tool from the Cochrane Handbook will be used
for RCTs [16]. Should cross-over trials be included, then
additional areas of risk of bias will need to be assessed.
These relate to: (i) whether the cross-over design is suit-
able; (ii) whether there is a carry-over effect; (iii) whether
only first-period data are available; (iv) appropriate stat-
istical analysis; and (v) comparability of results with
those from parallel-group trials [17].
For observational studies, the guidelines outlined in
Chapter 13 of the Cochrane Handbook will be followed
[18]. For controlled observational studies the domains in
the risk of bias tool for RCTs can be used as a minimum
assessment (accepting that the studies are not rando-
mised). The most relevant criteria for assessment in this
area are likely to relate to how the groups were selected,
differences in patient characteristics, loss to follow-up
and biases and confounding in outcome assessment.
For uncontrolled observational studies a tailored as-
sessment tool will be developed for this review based on
existing tools (such as the Downs and Black instrument
[19] or the Newcastle Ottawa scale [20]). Criteria such
as a clear description of population characteristics, use
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and loss to follow-up are likely to be relevant.
In addition to methodological criteria listed above, the
GRADE framework [21] will be used to consider incon-
sistency between studies, precision of results, likelihood
of publication bias and applicability of results to popula-
tion(s) of interest.
Analysis
Narrative synthesis of evidence will be undertaken for all
included studies. Results are likely to be presented using a
number of different outcome statistics, for example, mean
difference, relative risk, hazard ratio and so on. This may
be the case even for the same outcome, for example, ad-
missions to hospital could be reported as mean number of
admissions per patient or total number of admissions. Sur-
vival could be reported as time-to-event data or as relative
risk. Time points of reporting are also likely to vary across
studies. The relevance of short-term outcome assessment
is often related to underlying population risk for the out-
come in question. For example, patients discharged from
hospital after intensive emergency treatment for an ex-
acerbation of their COPD are at higher risk of a recurrent
exacerbation in the immediate aftermath (for example
three months) than patients who have been stable without
a severe exacerbation for many months. Where appropri-
ate, meta-analytic methods will be employed to combine
data reported by the same outcome statistic across the
same, or very similar time points; summary statistics will
most likely be pooled relative risk for dichotomous out-
comes, pooled mean difference for continuous outcomes
or pooled hazard ratios. This may involve conversion of
different statistics into a single, consistent measure, where
appropriate assumptions are met, for example by using
the method of Parmar to obtain hazard ratios from dichot-
omous data [22]. Standardised mean differences will be
considered if the same outcome is measured using differ-
ent assessment tools. Final choice of summary statistic
and method of meta-analysis will be guided by the consid-
erations outlined in Chapter 9 of the Cochrane Handbook
[23]. Assessment of clinical and methodological hetero-
geneity will be used to determine whether a fixed or
random-effects model is the most appropriate, rather than
relying on the tests of heterogeneity from a fixed-effect
model to make such a decision [24]. The I2 statistic (which
gives the percentage of the total variability in the data due
to between-study heterogeneity) and the tau-squared stat-
istic (which gives an estimate of the between-study vari-
ance) will be reported where appropriate. Evidence from
RCTs and observational studies will not be quantitatively
combined, but presented separately.
Consideration may need to be given on whether to in-
corporate cross-over trials into any meta-analyses.
Should cross-over trials be included in a meta-analysisthen separate analyses for parallel and cross-over studies
will also be presented [17].
For each meta-analysis containing 10 or more studies,
the likelihood of publication bias will be investigated
through the construction of funnel plots and appropriate
statistical tests for small-study effects (such as the Peters
Test [25]); that is, the tendency for smaller studies to
provide more positive findings. It is well recognised that,
especially where heterogeneity exists, publication bias
may be one of a number of reasons for any small-study
effects identified. The restriction of 10 studies is due to
the low power of identifying small-study effects with few
studies [16]. Where studies have reported time-to-event
analyses, meta-analysis using the extracted hazard ratios
and their variances will be undertaken, if possible.
The potential for indirect comparisons/multiple treat-
ment comparisons will be explored, for example if there
are RCTs comparing different types of NIV interventions
respectively, but with a common comparator (for example,
NIV1 versus standard care and NIV2 versus standard care).
A number of key assumptions would have to be met, in-
cluding that of homogeneity and exchangeability of partic-
ipants between trials [26]. The similarity of trial and
population characteristics within and between trials will
therefore be assessed qualitatively and statistically; how-
ever, if the trials are small there will be limited power to
assess the statistical inconsistency of any direct and indir-
ect comparisons. If such comparisons are deemed pos-
sible, a Bayesian approach, to take into account parameter
uncertainty and allow for probability statements and rank-
ing of treatment modalities, will be used. It is likely that
vague priors will need to be used and sensitivity to vari-
ation in these will be investigated.
Subgroup analysis
As NIV is becoming easier and cheaper to use in prac-
tice, knowledge about how and when to use it, as well as
in whom it is most effective, becomes of key clinical and
budgetary significance. To aid this and to further assist
economic model parameterisation (see below) a priori
data analysis of relevant subgroups will be undertaken
where deemed appropriate. Where data allows, such
analysis could include grouping by clinically perceived
effect modifiers such as type of ventilation (for example
pressures), patient interface (face/nasal mask), number
of hours of use per day of NIV (where there are clear
differences in trial protocols), patients on/not on LTOT
and severity of disease (including frequent versus non-
frequent exacerbators). Severity of disease may not al-
ways be well described, but where possible populations
will be identified according to, for example, the GOLD
criteria (2011) [4] and patients classified as ‘very severe’
may be compared to patients of other grades of severity
(‘mild’, ‘moderate’, ‘severe’). Sensitivity analysis may be
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mixed population of those relevant and not relevant to
the project. We are unlikely to assess the robustness of
any meta-analysis conclusions to varying study quality,
unless a clear difference in methodological quality is
identified between groups of included studies.
Cost-effectiveness
Searches
Strategies will include terms relating to cost, cost-effectiveness
and QoL.
Study selection
Inclusion criteria for population, intervention and com-
parator will be the same as for the clinical effectiveness
systematic review. Inclusion criteria for study design will
target cost-analysis, cost-effectiveness, cost-utility and
cost-benefit studies and decision model-based analyses.
Outcomes will be QoL, costs and incremental cost-
effectiveness ratios.
Quality assessment
Quality assessment will be appropriate to the study de-
sign, for example, the Drummond checklist [27] for eco-
nomic evaluations and the Philips checklist [28] for
model-based analyses.
Analysis
Each included study will be narratively reviewed and
similarities and differences between studies described
and tabulated. A prior assumption is that few economic
studies exist, therefore, the primary aim is to confirm or
refute this assumption and also to identify additional pa-
rameters for the cost part of the economic evaluation
not provided by the clinical effectiveness review.
Economic evaluation
An economic evaluation will be carried out from a
National Health Service (NHS) and Personal Social Services
(PSS) perspective, to take into account both healthcare
and social care costs of COPD. If data on the impact of
stable end-stage COPD on carers is available from the
literature, then a wider societal perspective will be con-
sidered in a sensitivity analysis, taking into account costs
and outcomes associated with informal care. The model
will determine the cost-effectiveness of NIV in a non-
hospital setting, in patients with stable end-stage COPD,
compared with standard care.
The economic evaluation will involve developing a
Markov-type, state transition model. This is the most
appropriate model type for this decision problem as the
model can represent a chronic disease such as COPD
where patients change health states over time. It is antic-
ipated the model will have a short time cycle (forexample a month) to account for exacerbations resulting
in Accident and Emergency attendance and hospital ad-
mission, which will in turn impact on healthcare costs,
QoL and survival. The time horizon of the model will be
patient lifetime, which, due to the age of the patients
and the high level of mortality, is unlikely, for most pa-
tients, to extend beyond five years. Findings from the
systematic reviews of clinical and cost-effectiveness will
be used to inform the economic evaluation and populate
the model.
Additional targeted searches may be performed on an
ad hoc basis to obtain information to populate model pa-
rameters. Modelling studies that consider NIV treatment
in other patient populations (for example muscular dys-
trophy) may be consulted to identity relevant cost data.
Standard sources of unit costs will be utilised, with add-
itional costs obtained from healthcare providers when no
relevant published data can be found. QoL data will be
determined from previously published studies. In the ab-
sence of QoL information from utility-based measures,
data from disease-specific tools such as the St George’s
Respiratory Questionnaire will also be sought and a map-
ping algorithm applied to predict utility scores [29].
For each important model parameter, we will deter-
mine a point estimate with a range of possible values
(for example confidence intervals) and construct a prob-
ability distribution around that point estimate. Base case
evaluation will be based on the most likely estimates.
Discounting will be applied at the standard rate of 3.5%
to both costs and outcomes. Univariate and probabilistic
sensitivity analyses will be conducted to deal with uncer-
tainty in model parameters and quantify the overall
decision uncertainty. Based on findings from the effect-
iveness review and estimated costs, the economic evalu-
ation may consider alternative patient subgroups and
additional scenarios where appropriate. A value of infor-
mation (VoI) analysis may be considered, if deemed rele-
vant, in order to explore whether further research is
required and to support recommendations for the re-
search agenda in this clinical area.Discussion
COPD continues to be a massive health burden world-
wide. COPD patients admitted to hospital with an ex-
acerbation are reaping the benefits from improvements
in standard medical treatment, including the use of in-
hospital NIV. Physiological reasons exist to why the
long-term use of NIV outside the hospital setting may
prevent hospital admissions for acute exacerbations.
There is much variability in the application of non-
hospital NIV for COPD and the hope is to identify
whether there is an actual benefit to patients and at what
cost. NIV is becoming easier and cheaper to use in
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to use it is of key clinical and budgetary significance.
Appendix 1. Sample search strategy for MEDLINE
Database: MEDLINE (Ovid) 1948 to June Week 2 2011
1. chronic obstructive pulmonary disease.mp. or exp
Pulmonary Disease, Chronic Obstructive/
2. copd.mp.
3. chronic obstructive lung disease.ti,ab..
4. chronic obstructive airway disease.ti,ab.
5. chronic respiratory disorder$.ti,ab.
6. smoking-related lung disease$.ti,ab.
7. Pulmonary Emphysema/
8. exp Bronchitis/
9. emphysema.mp.
10. or/1-9
11. noninvasive ventilation.ti,ab.
12. non-invasive ventilation.ti,ab.
13. exp positive-pressure respiration/or intermittent
positive-pressure ventilation/
14. npvv.ti,ab..
15. cpap.ti,ab.
16. bipap.ti,ab.
17. bi-level ventilation.ti,ab.
18. niv.ti,ab.
19. nippv.ti,ab.
20. positive pressure ventilation.ti,ab.
21. (non-invasive adj2 ventilation).ti,ab.
22. or/11-21
23. 10 and 22
Abbreviations
COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory
volume in one second; FVC: forced vital capacity; LTOT: long-term oxygen
therapy; NIV: non-invasive ventilation; PaCO2: partial pressure of carbon
dioxide in arterial blood; QoL: quality of life; RCT: randomised controlled trial;
VoI: value of information.
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